Is Descovy really the better option?
When the FDA approved Gilead’s Truvada (emtricitabine/tenofovir disoproxil) for HIV PrEP in 2012, it was a revolutionary step forward. The drug was safe and up to 99 percent effective in preventing HIV infection in at-risk individuals. Then in 2019, Gilead received FDA approval for a second drug for PrEP called Descovy (emtricitabine/tenofovir alafenamide), with equivalentRead more …Is Descovy really the better option? originally appeared inKevinMD.com. (Source: Kevin, M.D. - Medical Weblog)
Source: Kevin, M.D. - Medical Weblog - December 12, 2021 Category: General Medicine Authors: < span itemprop="author" > < a href="https://www.kevinmd.com/blog/post-author/frank-f-zhou" rel="tag" > Frank F. Zhou < /a > < /span > Tags: Meds Infectious Disease Medications Source Type: blogs
Drugs for COVID-19: A Publishing Epidemic
As of April 9, PubMed listed 2,868 scientific publications which incorporate the word “COVID”. 323 of these (11.3%) were related to drugs under study for treatment of the disease. No fewer than thirty-one such drugs had been proposed since this pandemic first appeared on the planet four months earlier.
Graph 1 depicts the cumulative numbers of COVID-19 infection (per 100,000 global population) and introductions of relevant drugs into the Literature during February 14 to April 3. Note that both increased by a factor of approximately 16-fold during this period.
In a...
Source: GIDEON blog - April 12, 2020 Category: Databases & Libraries Authors: Uri Blackman Tags: Epidemiology Graphs Source Type: blogs
PrEP prevents HIV — so why aren’t more people taking it?
Each year, 1.7 million people globally are newly infected with HIV — more than 38,000 in the United States alone. This year, President Trump announced a 10-year initiative aimed at reducing new HIV infections in the US, and ultimately ending an epidemic that has plagued this country, and the world, since HIV first emerged in the early 1980s. A key part of that plan is pre-exposure prophylaxis or PrEP, a daily medication to help prevent HIV that is recommended for people at high risk. Recently, the FDA approved a new formulation of PrEP for many — but not all — of those at risk.
What is PrEP and who should consider it...
Source: Harvard Health Blog - October 4, 2019 Category: Consumer Health News Authors: Robert Goldstein, MD, PhD Tags: Health HIV Infectious diseases Men's Health Sexual Conditions Women's Health Source Type: blogs
MKSAP: 44-year-old man with HIV, hypertension, and hyperlipidemia
Test your medicine knowledge with the MKSAP challenge, in partnership with the American College of Physicians. A 44-year-old man is evaluated in the office during a routine visit. Medical history is significant for HIV diagnosed at age 25 years, hypertension, and hyperlipidemia. He is a current smoker. Medications are chlorthalidone, tenofovir-emtricitabine, and raltegravir. On physical examination, the […]Find jobs at Careers by KevinMD.com. Search thousands of physician, PA, NP, and CRNA jobs now. Learn more. (Source: Kevin, M.D. - Medical Weblog)
Source: Kevin, M.D. - Medical Weblog - May 18, 2019 Category: General Medicine Authors: < span itemprop="author" > < a href="https://www.kevinmd.com/blog/post-author/mksap" rel="tag" > mksap < /a > < /span > Tags: Conditions Cardiology Infectious Disease Source Type: blogs
MKSAP: 53-year-old woman with hypertension and chronic active hepatitis B infection
Test your medicine knowledge with the MKSAP challenge, in partnership with the American College of Physicians. A 53-year-old woman is evaluated during a routine follow-up visit. Medical history is significant for hypertension and chronic active hepatitis B infection. Her hepatitis B infection has been treated with tenofovir for the p ast 5 years with suppression of her serum […]Find jobs at Careers by KevinMD.com. Search thousands of physician, PA, NP, and CRNA jobs now. Learn more. (Source: Kevin, M.D. - Medical Weblog)
Source: Kevin, M.D. - Medical Weblog - December 8, 2018 Category: General Medicine Authors: < a href="https://www.kevinmd.com/blog/post-author/mksap" rel="tag" > mksap < /a > Tags: Conditions Nephrology Source Type: blogs
MKSAP: 34-year-old man with slow-growing lesions
Test your medicine knowledge with the MKSAP challenge, in partnership with the American College of Physicians.
A 34-year-old man is evaluated for several slow-growing lesions on his penis. He first noticed the wart-like growths 3 years ago, and they have progressively enlarged. He was treated with topical cryotherapy six times and topical imiquimod over the past year without improvement; the lesions have continued to enlarge. Medical history is significant for HIV infection. Medications are tenofovir, emtricitabine, and efavirenz.
On physical examination, vital signs are normal. Multiple red to brown verrucous papules wi...
Source: Kevin, M.D. - Medical Weblog - October 20, 2018 Category: General Medicine Authors: < a href="https://www.kevinmd.com/blog/post-author/mksap" rel="tag" > mksap < /a > Tags: Conditions Infectious Disease Source Type: blogs
Tropical Travel Trouble 009 Humongous HIV Extravaganza
LITFL • Life in the Fast Lane Medical Blog LITFL • Life in the Fast Lane Medical Blog - Emergency medicine and critical care medical education blog
aka Tropical Travel Trouble 009
The diagnosis of HIV is no longer fatal and the term AIDS is becoming less frequent. In many countries, people with HIV are living longer than those with diabetes. This post will hopefully teach the basics of a complex disease and demystify some of the potential diseases you need to consider in those who are severely immunosuppressed. While trying to be comprehensive this post can not be exhaustive (as you can imagine any patient with a low ...
Source: Life in the Fast Lane - July 7, 2018 Category: Emergency Medicine Authors: Amanda McConnell Tags: Clinical Cases Tropical Medicine AIDS art cryptococcoma cryptococcus HIV HIV1 HIV2 PEP PrEP TB toxoplasma tuberculoma Source Type: blogs
PrEP: Protection against HIV in a pill?
HIV (the human immunodeficiency virus) weakens the human immune system and destroys the important cells that fight disease and infection. A person can get HIV when bodily fluids — including blood, semen, pre-seminal fluid, rectal fluids, or vaginal fluids of a person with the virus — come in contact with a mucous membrane or damaged tissue. HIV can be transmitted through breast milk, or when a contaminated needle or syringe comes into direct contact with the bloodstream.
There is no cure for HIV, but with proper medical care the virus and its effects can be controlled. HIV transmission can be reduced by consistent use ...
Source: Harvard Health Blog - May 18, 2018 Category: Consumer Health News Authors: Meera Sunder, MBBS, MRCOG Tags: Health HIV Infectious diseases Source Type: blogs
TWiV 483: Every infection is unhappy in its own way
Vincent and the Virals review undermining of antiviral effectiveness by genital inflammation, and heterogeneity of influenza virus infection in single cells. <span data-mce-type=”bookmark” style=”display: inline-block; width: 0px; overflow: hidden; line-height: 0;” class=”mce_SELRES_start”></span> Click arrow to play Download TWiV 483 (61 MB .mp3, 101 min) Subscribe (free): iTunes, RSS, email Become a patron of TWiV! Show notes at microbe.tv/twiv (Source: virology blog)
Source: virology blog - March 4, 2018 Category: Virology Authors: Vincent Racaniello Tags: This Week in Virology AIDS genital inflammation heterogeneity HIV influenza virus poliovirus PrEP single cell infection tenofovir viral viruses Source Type: blogs
MKSAP: 25-year-old man positive for hepatitis B surface antigen
Test your medicine knowledge with the MKSAP challenge, in partnership with the American College of Physicians.
A 25-year-old man is evaluated in follow-up after recently testing positive for hepatitis B surface antigen. He underwent testing as part of the immigration process from Somalia. Two other siblings also have hepatitis B virus (HBV) infection.
On physical examination, he is a young, healthy-appearing man. Vital signs are normal. No jaundice is noted, and the abdominal examination is unremarkable.
Laboratory studies:
Alanine aminotransferase
Normal
Aspartate aminotransferase
Normal
α-Fetoprotein
Normal
H...
Source: Kevin, M.D. - Medical Weblog - December 2, 2017 Category: General Medicine Authors: < a href="https://www.kevinmd.com/blog/post-author/mksap" rel="tag" > mksap < /a > Tags: Conditions Gastroenterology Oncology/Hematology Source Type: blogs
MKSAP: 32-year-old man with a rash on his face and midchest
Test your medicine knowledge with the MKSAP challenge, in partnership with the American College of Physicians.
A 32-year-old man is evaluated for a 2-week history of a rash on his face and midchest. He describes the rash as consisting of small, reddish “lumps” that are intensely itchy; they develop and begin to resolve with development of new lesions. He otherwise feels well. Medical history is significant for a recent diagnosis of HIV infection. Medications are tenofovir, emtricitabine, efavirenz, and trimethoprim-sulfamethoxazole. On physical examination, vital signs are normal.
The patient has 1- to 3-mm papules a...
Source: Kevin, M.D. - Medical Weblog - November 11, 2017 Category: General Medicine Authors: < a href="http://www.kevinmd.com/blog/post-author/mksap" rel="tag" > mksap < /a > Tags: Conditions Dermatology Infectious Disease Source Type: blogs
MKSAP: 32-year-old man with a rash on his face and midchest
Test your medicine knowledge with the MKSAP challenge, in partnership with the American College of Physicians.
A 32-year-old man is evaluated for a 2-week history of a rash on his face and midchest. He describes the rash as consisting of small, reddish “lumps” that are intensely itchy; they develop and begin to resolve with development of new lesions. He otherwise feels well.
Medical history is significant for a recent diagnosis of HIV infection. Medications are tenofovir, emtricitabine, efavirenz, and trimethoprim-sulfamethoxazole. On physical examination, vital signs are normal. The patient has 1- to 3-mm p...
Source: Kevin, M.D. - Medical Weblog - June 4, 2016 Category: Journals (General) Authors: mksap Tags: Conditions Dermatology Source Type: blogs
Switching HIV+ Patients From Stribld to Genvoya Improved Proteinuria but Not eGFR
CROI 2016 Conference
Abstract Number:
795
Safety of Tenofovir Alafenamide in Renal Impairment
Author(s):
Anton Pozniak2, Jose R Arribas3, Samir K. Gupta4, Frank A. Post5, Anchalee Avihingsanon6, Gordon Crofoot7, Kenneth A. Lichtenstein8, Moti Ramgopal9, Ploenchan Chetchotisa kd10, Marshall W. Fordyce11 Clinical Research, Gilead Sciences Inc, Foster City, CA, United States. 2 (Source: Nelson Vergel's HIV Blog)
Source: Nelson Vergel's HIV Blog - April 8, 2016 Category: Infectious Diseases Authors: Anonymous Source Type: blogs
Switching HIV+ Patients From Stribld to Genvoya Improved Proteinuria but Not eGFR
CROI 2016 Conference
Abstract Number:
795
Safety of Tenofovir Alafenamide in Renal Impairment
Author(s):
Anton Pozniak2, Jose R Arribas3, Samir K. Gupta4, Frank A. Post5, Anchalee Avihingsanon6, Gordon Crofoot7, Kenneth A. Lichtenstein8, Moti Ramgopal9, Ploenchan Chetchotisakd10, Marshall W. Fordyce11 Clinical Research, Gilead Sciences Inc, Foster City, CA, United States. 2 (Source: Nelson Vergel's HIV Blog)
Source: Nelson Vergel's HIV Blog - April 7, 2016 Category: Infectious Diseases Authors: Nelson Vergel Source Type: blogs
A Year in Review: FDA 2015 New Drug Approvals
The approval of first-of-a-kind drugs rose last year to forty-one, resulting in the highest level of newly approved U.S. drugs in nineteen years. The total number of new drugs approved last year was even higher at sixty-nine. The rising figures reflect an industry-wide desire to research and develop drugs for rare and hard-to-treat diseases.
The newly approved drugs serve to advance medical care and the health of patients suffering from many ailments, including various forms of cancer, heart failure, and cystic fibrosis. Additionally, more than 40% of the new therapies were approved for treatment of rare or "orphan" dise...
Source: Policy and Medicine - January 13, 2016 Category: American Health Authors: Thomas Sullivan - Policy & Medicine Writing Staff Source Type: blogs
